Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
will present additional data from patients with advanced melanoma from
the Phase IB trial of MK-3475 on Monday, Nov. 18 at the 10th
International Congress of the Society for Melanoma Research in
Philadelphia. MK-3475 is Mercks investigational anti-PD-1
immunotherapy.
Language:
English
Contact:
MerckMedia:Ian McConnell, 908-423-3046orClaire Mulhearn, 908-423-7425orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more